What Labs to Monitor on Peptide Therapy: A Practical Guide by Compound

Medical Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice. Laboratory monitoring requirements vary by individual — your prescribing provider should establish a monitoring plan specific to your medications, medical history, and risk factors. Do not adjust, start, or stop any therapy based on lab results without consulting a qualified healthcare provider.

One of the most consistent gaps in peptide therapy — particularly when obtained through wellness clinics rather than conventional medical practice — is inadequate monitoring. Patients receive prescriptions, reconstitute their peptides, and inject for months without anyone checking whether the therapy is producing physiologic or supraphysiologic effects, whether glucose tolerance has shifted, or whether early adverse signals are developing.

This is not about bureaucratic caution. It is about the basic pharmacology of compounds that act on hormone axes, metabolic pathways, and immune function. These systems have measurable outputs. Ignoring those outputs is not a treatment approach — it is guesswork.

This guide organizes monitoring by compound class, covering what to measure, at what intervals, and what results mean.

Universal Baseline: Before Starting Any Peptide Therapy

Regardless of which peptide you are starting, these baseline labs provide the foundation for detecting changes over time. Without a baseline, you cannot interpret whether a change in a value represents a treatment effect or a pre-existing condition.

Recommended baseline panel:

Test	Why It Matters
Complete metabolic panel (CMP)	Kidney function (creatinine, BUN, eGFR), liver enzymes (AST, ALT), electrolytes, glucose
Lipid panel	Cholesterol, LDL, HDL, triglycerides — altered by GH axis and GLP-1 therapies
CBC (complete blood count)	General health status, immune cell counts (relevant for immune-modulating peptides)
TSH + free T4	Thyroid function — altered by GH/IGF-1 axis; important baseline before secretagogue therapy
HbA1c	3-month average blood glucose — critical baseline for any GH secretagogue or GLP-1 therapy
Fasting insulin	Insulin sensitivity baseline — useful context for GH axis and metabolic interventions
Blood pressure (both arms, resting)	Baseline before PT-141 or any therapy that may affect BP

If you are starting a GH secretagogue specifically, also get:

Test	Why It Matters
IGF-1 (Insulin-like Growth Factor 1)	The primary downstream marker of GH axis activity; the single most important lab for GH secretagogue monitoring
DHEA-S	Often included in hormone panels at anti-aging clinics; useful age-related hormone baseline
Morning cortisol	GH and cortisol interact; useful baseline if adrenal function is a consideration

How to Get Labs: Clinical vs. Direct-to-Consumer Options

Labs can be obtained through your prescribing provider, through a primary care physician, or through direct-to-consumer services. Each has tradeoffs:

Through your prescribing provider: Billed to insurance if coded appropriately. Provider has access to results in real time. Monitoring results are part of your medical record. This is the preferred pathway — it creates continuity of care and gives your provider visibility into your response to treatment.

Through your PCP: Many peptide therapy patients don’t tell their PCP about their peptide protocols. This creates a clinical information gap that can affect safety — your PCP may interpret a rising IGF-1 or declining HbA1c without knowing why. Consider disclosing your peptide therapy to your PCP even if they didn’t prescribe it.

Direct-to-consumer lab services (LabCorp Patient, Quest Diagnostics, Labcorp OnDemand, Everlywell, Function Health): No provider referral required, typically paid out of pocket at transparent prices. IGF-1 at LabCorp Direct typically costs $50–90. Comprehensive metabolic panels are $25–50. These services are useful when a provider won’t order specific markers or when you need to monitor at intervals your provider doesn’t schedule. Limitation: results arrive in a patient portal without clinical interpretation — you need a provider relationship to contextualize unusual values.

Insurance coverage: Labs ordered for FDA-approved indications (HbA1c for diabetes management, lipid panel for dyslipidemia, TSH for thyroid disease) are typically covered. Labs ordered specifically for peptide therapy monitoring may not be, depending on how they are coded and your plan. Ask the billing office at your provider’s practice how monitoring labs will be submitted before you go for bloodwork.

Reading Results: What the Numbers Mean

IGF-1 Interpretation

IGF-1 is age- and sex-adjusted. A value that is “high” for a 60-year-old may be normal for a 30-year-old. Always use the reference ranges on your specific lab report — they are age-matched and sex-matched.

Key thresholds for GH secretagogue patients:

Below the age-matched lower limit of normal: Possible GH deficiency or poor response to therapy; discuss with your provider whether to adjust dosing or timing, or whether to evaluate for causes of GH suppression (obesity, hypothyroidism, cortisol excess). The cortisol excess mechanism is dual: first, glucocorticoids bind GR (glucocorticoid receptor) in hypothalamic periventricular nucleus neurons and increase somatostatin (SST) gene transcription via GRE (glucocorticoid response element) in the SST promoter → elevated SST secretion into the portal hypophyseal circulation → SSTR2/SSTR5 on pituitary somatotrophs → Gαi → reduced cAMP/PKA → blunted GHRHR signaling and suppressed GH pulse amplitude. Second, glucocorticoids act directly on somatotrophs: GR occupancy in these cells drives expression of SOCS2 (suppressor of cytokine signaling 2), which binds the GHR-associated JAK2 and targets it for ubiquitin-mediated degradation, attenuating GH’s own autocrine/paracrine amplification loop; GR also binds a negative GRE (nGRE) in the GHRHR promoter, directly suppressing GHRHR transcription and reducing the number of functional GHRH receptors available to drive GH release. The net result is both a reduced stimulus (less GHRHR on somatotrophs) and an increased brake (more SST from periventricular nucleus) — which is why Cushing’s syndrome and exogenous glucocorticoid therapy cause GH deficiency even when GHRH secretion is intact.
Within the age-matched normal range: Therapeutic range — the goal for most patients using GH secretagogues for wellness or anti-aging purposes. The objective is not to maximize IGF-1 but to achieve a level consistent with healthy reference values
Above the age-matched upper limit of normal (supranormal): Signal to reduce dose or pause therapy. Persistently supranormal IGF-1 is associated with increased risk of acromegaly-related complications (glucose intolerance, joint effects, cardiovascular effects) and with the cancer risk signals observed in epidemiological studies of naturally elevated IGF-1 (Renehan et al., 2004)

Timing of IGF-1 draw: IGF-1 has relatively little diurnal variation compared to GH (which pulses dramatically across the day). A morning draw is conventional but any consistent time works for serial monitoring — the key is consistency so trends are interpretable. The mechanistic reason for this stability lies in IGF-1’s circulating carrier system. Approximately 75–80% of circulating IGF-1 is bound within a ternary complex consisting of IGF-1 itself + IGFBP-3 (insulin-like growth factor binding protein 3, MW ~43 kDa) + ALS (acid-labile subunit, encoded by IGFALS, MW ~86 kDa). IGFBP-3 is secreted from hepatocytes under GH/JAK2/STAT5b transcriptional control; ALS is also hepatically produced via the same STAT5b axis and assembles with IGFBP-3:IGF-1 binary complexes in the circulation to form the ~150 kDa ternary structure. The plasma half-life of IGF-1 within this ternary complex is approximately 12–15 hours, compared to free IGF-1’s half-life of ~10 minutes: free IGF-1 at 7.6 kDa is small enough to pass through the glomerular filtration barrier (GFR cutoff ~40 kDa for unbound peptides) and is rapidly cleared by renal megalin/LRP2-mediated tubular endocytosis, whereas the 150 kDa ternary complex is too large for glomerular filtration and is additionally protected from circulating proteases by the binding contacts between IGFBP-3’s C-terminal domain and ALS’s leucine-rich repeat scaffold. The consequence for monitoring is mathematically straightforward: each episodic GH pulse (20–40 minutes duration, occurring 4–6 times per day predominantly nocturnally) triggers a brief JAK2/STAT5b burst in hepatocytes → incremental new IGF-1 and IGFBP-3 production → released IGF-1 is immediately captured by the IGFBP-3/ALS reservoir → added to a circulating pool with a 12–15 hour decay constant. The long decay time integrates all daily GH pulses into a near-constant circulating level, analogous to how a large reservoir smooths an intermittent inflow — which is why circulating IGF-1 varies less than 10% across the day despite GH itself varying 10–100-fold between pulse peaks and nadirs. A blood draw taken at 8 AM versus 8 PM from the same individual will yield essentially identical IGF-1 values, making any consistent draw time reliable for serial trend monitoring.

HbA1c Interpretation

HbA1c reflects average blood glucose over approximately 3 months. The biochemical reason for this window is the lifespan of red blood cells (RBCs). Glucose reacts non-enzymatically with hemoglobin via the Maillard reaction: circulating glucose condenses with the free amino group at the N-terminal valine of the hemoglobin beta chain → forms an unstable Schiff base (aldimine) intermediate → spontaneously undergoes the Amadori rearrangement → becomes a stable ketoamine (HbA1c). Unlike enzymatic reactions, this glycation is irreversible for the life of the RBC, and its rate is proportional to the ambient glucose concentration the RBC has been exposed to. Because RBCs circulate for approximately 120 days before being cleared by the spleen, the HbA1c value at any point in time reflects the weighted average glucose exposure across that ~120-day window — with more recent weeks contributing proportionally more (because the RBC pool contains more young, recently-glycated cells than cells close to their end-of-life). The 3-month averaging window is therefore not an arbitrary clinical convention but a direct consequence of RBC turnover biology. This explains why HbA1c does not respond to acute dietary changes and why serial measurements 3 months apart are the minimum interval to detect meaningful therapeutic change.

Normal: below 5.7%
Pre-diabetes: 5.7–6.4%
Diabetes: 6.5% or above

For GLP-1 users starting with pre-diabetes or diabetes, declining HbA1c is a primary treatment objective. For GH secretagogue users, monitoring for rising HbA1c (reflecting GH’s glucose-raising effect) is protective. A rise from below 5.7% to the pre-diabetes range during GH secretagogue therapy warrants dose adjustment discussion with your provider.

Kidney Function (eGFR) Interpretation

eGFR (estimated glomerular filtration rate) is the primary kidney function metric. The biochemical basis for using creatinine to estimate GFR is specific: creatinine is produced at a near-constant daily rate through the spontaneous, non-enzymatic cyclization of phosphocreatine in skeletal muscle (yielding creatinine at approximately 1–2% of total creatine pool per day, proportional to muscle mass). Once in circulation, creatinine has properties that make it an ideal GFR surrogate: it is small (~113 Da), freely filtered at the glomerular basement membrane (no significant protein binding to limit filtration), not appreciably reabsorbed by proximal or distal tubular cells (unlike glucose, amino acids, and bicarbonate, which have active reabsorption transporters), and not significantly secreted at physiological serum concentrations (tubular OAT secretion of creatinine increases slightly at elevated serum concentrations but is minor at normal ranges). Because creatinine is produced at a steady rate and cleared almost entirely by filtration, the serum creatinine level is mathematically inversely related to GFR: as filtration falls, creatinine accumulates. The CKD-EPI 2021 equation (the current clinical standard, which eliminated race as a variable) converts serum creatinine, age, and sex into an estimated GFR in mL/min/1.73m² — producing a continuous number from the single routinely-measured metabolite. The reason GFR estimation matters for peptide dosing is that renally cleared compounds accumulate predictably as GFR declines: drugs or metabolites filtered through the glomerulus and dependent on urinary excretion for elimination have plasma half-lives that scale approximately inversely with eGFR when tubular secretion is the dominant clearance mechanism. For GLP-1 drugs specifically, the relevant concern is not the drugs’ own renal clearance (semaglutide and tirzepatide are both primarily cleared by proteolytic degradation and hepatic metabolism, not urinary filtration — their half-lives do not substantially change with moderate kidney impairment). Instead, the eGFR monitoring concern in GLP-1 users at low eGFR is pharmacodynamic: patients with compromised renal function have reduced tubular Na⁺/K⁺-ATPase pump reserve and impaired aldosterone responsiveness → less capacity for volume compensation during the GI-driven fluid losses (nausea, reduced intake) that GLP-1 drugs routinely produce → acute-on-chronic volume depletion → transient eGFR drop superimposed on already-reduced baseline → prerenal AKI risk substantially higher per GI episode than in a patient with normal renal reserve. This explains why clinical guidance becomes increasingly conservative as eGFR falls, even though the pharmacokinetics of GLP-1 drugs themselves are relatively renal-independent.

eGFR ≥90: Normal kidney function
eGFR 60–89: Mildly reduced — usually does not affect dosing but warrants monitoring
eGFR 30–59: Moderately reduced — many peptide dosing regimens require adjustment; GLP-1 drugs may be dose-modified
eGFR <30: Severely reduced — GLP-1 drug use requires careful specialist review; most compounded peptide protocols are not studied in this population

GLP-1 Receptor Agonists (Semaglutide, Tirzepatide, Liraglutide)

GLP-1 drugs have the best-characterized monitoring requirements of any peptide class, because they went through FDA approval with extensive pharmacovigilance. The prescribing information provides specific guidance — but wellness clinic prescribers sometimes skip it.

What to Monitor and When

Blood glucose and HbA1c

Baseline before starting
HbA1c at 3 months, then every 3–6 months depending on whether you have diabetes
Fasting glucose at each monitoring visit
Why: GLP-1 drugs significantly lower blood glucose. If you are on insulin or sulfonylureas, the risk of hypoglycemia increases as weight loss improves insulin sensitivity. Even without diabetes medications, glucose trends confirm metabolic improvement.

Blood pressure

Baseline before starting
At each monitoring visit (every 1–3 months during active dose escalation)
Home monitoring 2–3x/week during significant weight loss phases
Why: GLP-1-induced weight loss progressively lowers blood pressure. Two direct GLP-1R-mediated mechanisms contribute independent of weight loss. First, renal natriuresis: GLP-1R on proximal convoluted tubule cells → Gs/cAMP → PKA phosphorylates NHE3 (Na⁺/H⁺ exchanger 3, SLC9A3) at Ser552 and Ser605 in its C-terminal regulatory domain → phosphorylation drives NHE3 into subapical endosomes via NHERF1/Ezrin scaffolding disruption → reduced NHE3 apical surface expression → less Na⁺ reabsorption from the tubular lumen → increased urinary sodium excretion (natriuresis) → reduced extracellular fluid volume → lower cardiac preload → modestly reduced systolic BP (Crajoinas et al., 2011, PMID:21555512). Second, direct vascular endothelial vasodilation: GLP-1R on vascular endothelial cells → Gs/cAMP → PKA phosphorylates eNOS at Ser1177 (the same activating site used by Akt during exercise-induced vasodilation) → eNOS shifts to its high-output active configuration → endothelial NO production. The mechanism by which Ser1177 phosphorylation activates eNOS is structurally distinct from simple allosteric activation: eNOS is a constitutive homodimer in which each monomer contains an oxygenase domain (N-terminal; harboring the heme iron, BH4 cofactor, and L-arginine substrate site where NO is generated) and a reductase domain (C-terminal; containing NADPH, FAD, and FMN electron carriers). Under basal conditions, an autoinhibitory hairpin loop within the FMN-binding subdomain of the reductase domain folds across the protein surface and sterically occludes the FMN-subdomain/oxygenase-domain docking interface — physically preventing the final electron transfer step from FMN to the oxygenase heme → NO production is minimal. Calmodulin (CaM) bound at elevated Ca²⁺ (residues 492–511, the CaM-binding domain) displaces the autoinhibitory loop, enabling the FMN subdomain to dock with the oxygenase domain heme and complete the NADPH → FAD → FMN → heme electron transfer → maximal NO output. Ser1177 phosphorylation by PKA or Akt acts through the same steric mechanism but via a different structural route: Ser1177 is located in the FMN subdomain immediately adjacent to the autoinhibitory loop’s membrane-proximal hinge; the phosphate group’s added negative charge at this position destabilizes the loop’s interaction with its hydrophobic docking platform on the FMN subdomain surface, partially releasing the autoinhibitory constriction even at basal Ca²⁺ concentrations. The result is that Ser1177 phosphorylation reduces the Ca²⁺ concentration required for half-maximal eNOS activation (lowers the EC₅₀ for CaM-driven activation) and increases the maximum electron transfer rate per unit time — enabling GLP-1R/Gs/cAMP/PKA to drive endothelial vasodilatory NO production in the absence of the full Ca²⁺ transient that unphosphorylated eNOS would require → NO diffuses into adjacent vascular smooth muscle cells → activates sGC → cGMP → PKG → PKG phosphorylates and inhibits MLCK (myosin light chain kinase) → reduced myosin light chain phosphorylation → smooth muscle relaxation → arteriolar vasodilation → reduced peripheral vascular resistance → BP reduction. These direct mechanisms compound with weight-loss-driven RAAS suppression (adipose-derived angiotensinogen and ACE reduction, as described in the renoprotection section above), explaining why clinical trial BP reductions often exceed what weight loss alone would predict. Patients on antihypertensive medications may become over-treated. Symptoms of low BP (dizziness on standing, lightheadedness) warrant a same-week provider call.

Kidney function (creatinine, eGFR)

Baseline, then every 6–12 months
More frequently if kidney function is borderline or if dehydration episodes occur
Why: GLP-1 drugs have demonstrated kidney protection in large RCTs (FLOW trial: 24% reduction in CKD composite endpoint in semaglutide arm, Perkovic et al., 2024). However, significant nausea, vomiting, or reduced fluid intake can cause dehydration-related acute kidney stress.

The renoprotective mechanism underlying the FLOW trial finding operates through three parallel pathways rather than a single dominant mechanism. The first is intraglomerular pressure reduction: GLP-1-induced weight loss → reduced visceral adiposity → reduced renin-angiotensin-aldosterone system (RAAS) activation (visceral adipose tissue expresses renin, angiotensinogen, and ACE, all of which contribute to elevated circulating angiotensin II in obese patients; weight loss reduces this adipose-derived RAAS output) → reduced angiotensin II → less AT1R-mediated efferent arteriole constriction → reduced intraglomerular hydraulic pressure → less mechanical stretch-driven podocyte injury and less hyperfiltration-mediated nephron loss over years. The second is direct GLP-1R-mediated anti-inflammatory and anti-fibrotic signaling: GLP-1R is expressed on mesangial cells, podocytes, and proximal tubular cells; GLP-1R activation → Gs/cAMP/PKA on these cells → PKA phosphorylates NF-κB p65 Ser276, reducing its transcriptional activity at pro-inflammatory gene promoters (TNF-α, IL-6, MCP-1) in mesangial cells → less macrophage recruitment into the glomerulus → reduced mesangial matrix expansion (TGF-β1/SMAD2/3-driven collagen deposition is attenuated when the upstream inflammatory trigger is lower). In tubular cells, cAMP/PKA → Nrf2 activation (via KEAP1 phosphorylation and reduced degradation of Nrf2) → HO-1 and NQO1 transcription → reduced tubular oxidative stress. The third pathway is blood pressure reduction: semaglutide’s natriuretic and weight loss effects modestly reduce systemic blood pressure (3–5 mmHg systolic in FLOW trial patients) → sustained reduction in glomerular hydraulic pressure independent of RAAS mechanism → attenuated pressure-driven glomerulosclerosis in patients with pre-existing CKD who are particularly vulnerable to hypertensive nephron loss. Monitoring eGFR serially during GLP-1 therapy documents this protective trajectory — and catches the uncommon patient who develops dehydration-related prerenal azotemia from GI fluid loss, which produces a transient eGFR drop that resolves with adequate hydration but can be mistaken for disease progression without serial monitoring context.

Lipid panel

Baseline, then at 6 months and annually
Why: GLP-1 drugs generally improve lipid profiles — triglyceride reductions of 20–30% are common. Monitoring confirms benefit and catches unexpected changes. The triglyceride reduction operates through three mechanistically distinct arms acting simultaneously. First, GLP-1R on hepatocytes → Gs/adenylyl cyclase/cAMP ↑ → PKA activation → PKA phosphorylates DGAT2 (diacylglycerol O-acyltransferase 2) at regulatory serine residues → reduced DGAT2 catalytic activity → less diacylglycerol + fatty acyl-CoA converted to triglyceride in the hepatic endoplasmic reticulum → less TG substrate available for VLDL particle assembly; VLDL assembly requires MTP (microsomal triglyceride transfer protein) to load TG onto nascent apoB100 — when hepatic TG synthesis falls, MTP has less substrate, fewer VLDL particles are fully lipidated and secreted, and plasma VLDL-TG output drops correspondingly. Second, GLP-1-stimulated insulin secretion from pancreatic β-cells → systemic insulin elevation → insulin upregulates LPL (lipoprotein lipase) expression and promotes its translocation to the luminal surface of capillary endothelium in adipose tissue and skeletal muscle → LPL hydrolyzes TG cores of circulating VLDL particles and chylomicron remnants at higher rates → plasma TG is cleared from the circulation faster, independent of hepatic output changes. Third, body weight reduction (even modest: 5–10%) → reduced adipose tissue mass → lower basal lipolysis → reduced free fatty acid (FFA) flux from adipose tissue to the liver via portal circulation → less FFA substrate for de novo lipogenesis (DNL: acetyl-CoA → malonyl-CoA → palmitate via FASN) and for DGAT2-mediated re-esterification → further reduction in hepatic VLDL-TG output. The observed 20–30% fasting TG reduction in clinical trials reflects all three arms — hepatic DGAT2 suppression, enhanced LPL-mediated clearance, and weight loss-driven FFA flux reduction — acting in parallel rather than any single dominant pathway.

Thyroid (TSH)

Baseline before starting
Annual TSH monitoring is reasonable for patients on long-term GLP-1 therapy, particularly if on levothyroxine replacement.
The FDA boxed warning on thyroid C-cell tumor risk observed in rodents requires that patients with personal or family history of medullary thyroid carcinoma or MEN2 not use GLP-1 drugs. Understanding why rodents are susceptible clarifies both the preclinical finding and its limited extrapolation to humans.

Rodent thyroid C-cells (parafollicular cells, the calcitonin-secreting population) express GLP-1 receptors at high density — approximately 5–10× higher than in human thyroid C-cells, as measured by radioligand binding and GLP-1R mRNA quantification in comparative histological series. When GLP-1R agonists occupy those receptors at sustained pharmacological concentrations, the C-cell transduction cascade runs: GLP-1R → Gs → adenylyl cyclase → cAMP ↑ → PKA activation, which drives two parallel proliferative outputs. First, PKA activates Rap1 (a cAMP-activated small GTPase, mechanistically distinct from Ras) → Rap1/B-Raf/MEK1/2/ERK1/2 → ERK-driven transcription of cyclin D1 and c-Myc → G1/S cell cycle progression → C-cell hyperplasia. Second, PKA/CREB drives transcription of calcitonin and calcitonin gene-related peptide (CGRP) genes, reinforcing C-cell secretory hypertrophy. With sustained pharmacological stimulation over months to years — the duration relevant to obesity and diabetes treatment — this proliferative cascade in high-GLP-1R-density rodent C-cells progresses from hyperplasia to frank medullary thyroid carcinoma in a dose- and duration-dependent manner in rat studies (PMID:18840764).

In human thyroid C-cells, GLP-1R mRNA and protein expression are substantially lower than in rodents — confirmed across autopsy series and surgical specimens. Consistent with this lower receptor density, large pharmacoepidemiological studies of GLP-1 agonist users have not identified increased MTC incidence relative to background population rates. The boxed warning therefore reflects a precautionary extrapolation from the rodent proliferative mechanism, not a confirmed human signal. The MEN2 contraindication has a separate rationale: MEN2 syndrome involves activating mutations in the RET proto-oncogene → constitutive RET kinase signaling — the molecular details: MEN2A mutations (most commonly C634F at the extracellular cysteine-rich domain) force constitutive RET dimerization, while MEN2B mutations (M918T in the kinase domain activation loop) shift RET into a constitutively active monomeric conformation; both converge on constitutive autophosphorylation of intracellular tyrosine residues including Tyr905/Tyr1015/Tyr1062. Tyr1062 is the critical docking site: it recruits the ShcC/Grb2/SOS adaptor complex → SOS (a RAS-GEF) → RAS-GTP → RAF/MEK/ERK activation → cyclin D1/c-Myc transcription → G1/S progression. Simultaneously, Tyr1062 recruits PI3K p85 → Akt → mTOR, adding a parallel proliferative arm. This constitutive RET→RAS/ERK and RET→PI3K/Akt signaling establishes a baseline C-cell proliferative drive already operating at constitutive maximum; any additional mitogenic input through the GLP-1R/Rap1/B-Raf/MEK/ERK axis converges on the same ERK→cyclin D1→cell cycle entry output, making the combination additive at the proliferative endpoint regardless of upstream pathway divergence — which is the mechanistic rationale for the MEN2 contraindication.

Heart rate

At each visit
Why: GLP-1 agonists modestly increase resting heart rate (typically 2–5 bpm). Clinically insignificant for most patients but worth documenting in those with arrhythmia history.

The mechanism behind this heart rate increase is direct pharmacology, not a downstream consequence of weight loss. GLP-1 receptors are expressed on sinoatrial (SA) node pacemaker cells, where they couple through Gs to adenylyl cyclase → cAMP elevation → protein kinase A (PKA) activation. PKA phosphorylates HCN4 (hyperpolarization-activated cyclic nucleotide-gated channel 4), the molecular basis of the cardiac “funny current” (If): phosphorylation at Ser671 shifts HCN4 activation kinetics, accelerating the rate of diastolic membrane depolarization in pacemaker cells → faster spontaneous action potential firing → increased intrinsic heart rate (PMID:11602614). A parallel contribution comes from central GLP-1R stimulation in brainstem autonomic nuclei (nucleus tractus solitarius/area postrema) → increased sympathetic outflow → norepinephrine release at β1-adrenergic receptors on the SA node → the same downstream cAMP/PKA/HCN4 pathway. The 2–5 bpm increase is present across the GLP-1 class independent of drug-specific structural differences, consistent with a receptor-mediated class effect. For most patients the magnitude is clinically inconsequential; for patients with pre-existing tachycardia, arrhythmia, or sympathomimetic medication use (e.g., stimulants, decongestants), this additive chronotropic signal warrants specific discussion with the prescriber.

Body composition (optional but valuable)

DEXA scan at baseline and at 6–12 months if available
Why: Scale weight does not distinguish fat loss from muscle loss. Muscle loss on GLP-1 therapy is a documented concern — 20–40% of weight lost may be lean mass in patients not following muscle-preserving protocols (Wilding et al., 2021). Body composition monitoring lets you verify you are losing fat, not lean mass.

The molecular basis for this disproportionate lean mass loss under GLP-1-induced caloric restriction operates through two converging arms. First, GLP-1 receptor activation compresses meal size and slows gastric emptying, which reduces the per-meal leucine bolus delivered to systemic circulation. Leucine is the primary amino acid sensor for mTORC1 activation: at sufficient concentrations, leucine binds Sestrin2, releasing the Sestrin2-GATOR2 inhibitory interaction → GATOR2 becomes free to suppress GATOR1 (a GAP for RagA/RagC) → RagA-GTP/RagC-GDP heterodimer recruits mTORC1 to the lysosomal membrane via the Ragulator scaffold → Rheb-GTP at the lysosomal surface completes mTORC1 activation → S6K1 (Thr389) and 4E-BP1 (Thr37/46, Ser65) phosphorylation → ribosome biogenesis and cap-dependent translation of myofibrillar proteins. When each meal delivers a sub-threshold leucine bolus — typically below ~3 g of leucine or ~25–30 g of total high-quality protein — this Sestrin2/GATOR2/mTORC1 cascade fails to achieve robust activation, and the muscle protein synthesis (MPS) rate falls below the resting muscle protein breakdown (MPB) rate even in the absence of frank amino acid deficiency (PMID:23459753).

The second arm involves the caloric deficit itself activating AMPK (AMP:ATP sensing via LKB1 → AMPK Thr172 phosphorylation). AMPK suppresses mTORC1 through two mechanisms simultaneously: phosphorylation of Raptor (Ser792) → mTORC1 complex dissociation, and phosphorylation of TSC2 (Thr1387) → enhanced RhebGAP activity → Rheb-GDP accumulation → mTORC1 loss of lysosomal activating signal. In parallel, AMPK activates ULK1 (Ser317, Ser777) → autophagy/mitophagy initiation. Protein catabolism is further amplified through FOXO3a: when Akt activity falls under low nutrient conditions, FOXO3a escapes Akt-mediated phosphorylation at Thr32/Ser253/Ser315 and translocates to the nucleus → transcriptional upregulation of the atrogenes MAFbx/atrogin-1 (an E3 ubiquitin ligase targeting MyoD and eIF3-f) and MuRF1 (an E3 ubiquitin ligase targeting myosin heavy chain, troponin I, and titin fragments) → ubiquitin-proteasome-mediated myofibrillar proteolysis (PMID:11544515).

This mechanistic framework explains why the standard countermeasures — maintaining protein intake at ≥1.6 g/kg/day distributed across meals with sufficient per-meal leucine density, and resistance training (which activates mTORC1 through a parallel Akt/TSC2 branch downstream of mechanical stretch and IGF-1R) — partially preserve lean mass despite the GLP-1-driven caloric restriction. DEXA monitoring makes this distinction visible: fat mass reduction with preserved or minimally reduced lean mass indicates the protocol is working appropriately; progressive lean mass loss signals a need to adjust protein distribution or add resistance training stimulus.

GLP-1 Monitoring Schedule

Lab	Baseline	3 months	6 months	12 months	Annually
HbA1c	✓	✓	✓	✓	✓
Fasting glucose	✓	✓	✓	✓	✓
Blood pressure	✓	✓	✓	✓	✓
Lipid panel	✓		✓		✓
eGFR/creatinine	✓		✓		✓
TSH	✓			✓	✓
Heart rate	✓	✓	✓	✓	✓

Red-Flag Symptoms That Warrant Immediate Contact

Severe, persistent abdominal pain (possible pancreatitis). GLP-1R is expressed on pancreatic ductal epithelial cells and on acinar cells. The proposed mechanism for GLP-1-associated pancreatitis: GLP-1R/Gs/cAMP → Epac (exchange protein directly activated by cAMP) activates Rap1, which in ductal cells drives B-Raf/MEK/ERK → cyclin D1 → ductal epithelial cell proliferation; separately, PKA can stimulate acinar cell secretion. At pharmacological GLP-1R agonist concentrations, this ductal proliferative drive may increase ductal epithelial cell mass and alter ductal lumen geometry without a proportionate increase in bicarbonate-driven pancreatic juice flow rate — creating relative stasis of the enzyme-rich pancreatic secretion. Retained, concentrated pancreatic juice contains trypsinogen and other zymogens that under normal conditions are diluted by bicarbonate-rich flow and only activated by enteropeptidase (enterokinase) in the duodenal lumen. With relative ductal obstruction or stasis: minor ductal epithelial injury releases cathepsin B from lysosomes into the duct lumen → cathepsin B cleaves the trypsinogen activation peptide → intraluminal trypsin activation begins before the duodenum → trypsin activates other zymogens (chymotrypsinogen, proelastase, kallikreinogen) within the duct → autodigestive cascade → pancreatitis. Why causality is contested: (1) type 2 diabetes itself approximately doubles pancreatitis risk, independent of any medication — GLP-1 drugs are prescribed predominantly to people with diabetes, making confounding by indication difficult to separate from true drug effect; (2) large pharmacoepidemiological studies with active comparators (matched sulfonylurea or metformin users with equivalent diabetes severity) have generally not produced statistically significant pancreatitis risk elevations above the diabetic background rate; (3) AERS (FDA Adverse Event Reporting System) data, which generated the initial signal, is subject to reporting bias and cannot establish causality. The FDA added a precautionary warning, and acute pancreatitis appears on prescribing information for all GLP-1 drug classes. The clinical practical implication: severe, persistent mid-epigastric or left upper quadrant pain radiating to the back during GLP-1 therapy warrants same-day evaluation regardless of whether causality is established)
Yellowing of skin/eyes, dark urine, or right upper quadrant pain (possible gallbladder disease — GLP-1 drugs increase gallstone risk through two mechanistically distinct routes that compound one another during therapy). Route 1 — pharmacological gallbladder hypomotility: GLP-1R is expressed on gallbladder smooth muscle and on enteric neurons innervating the biliary tree. At pharmacological GLP-1R agonist concentrations: GLP-1R/Gs/adenylyl cyclase → cAMP ↑ → PKA activation → PKA phosphorylates MLCK (myosin light chain kinase) at its calmodulin-binding regulatory domain → MLCK is inactivated → myosin light chain (MLC20) remains hypophosphorylated → gallbladder smooth muscle cannot contract against the bile volume → gallbladder ejection fraction falls. Under normal postprandial physiology, endogenous GLP-1 participates in coordinating intestinal motility; at the sustained pharmacological concentrations produced by GLP-1R agonists, the dominant effect is tonic gallbladder smooth muscle relaxation and blunted cholecystokinin (CCK)-driven contraction. Prolonged bile residence time allows passive water reabsorption from stagnant bile → the cholesterol-to-bile-salt ratio rises above the critical micellar concentration threshold → cholesterol nucleation begins → cholesterol monohydrate crystals form → gallstone development over weeks to months. Route 2 — rapid weight loss-driven biliary cholesterol loading: GLP-1-induced caloric restriction mobilizes adipose lipids → elevated FFA flux to the liver → increased hepatic de novo cholesterol synthesis and enhanced biliary cholesterol secretion via ABCG5/ABCG8 heterodimer transporters on the canalicular membrane → bile becomes transiently more cholesterol-saturated during rapid weight loss phases, exceeding the solubilization capacity of the bile acid pool. Both routes operate simultaneously: pharmacological hypomotility traps cholesterol-supersaturated bile in a poorly contracting gallbladder, amplifying nucleation kinetics well beyond what either factor would produce independently.
Persistent severe nausea/vomiting with inability to keep fluids down — beyond dehydration discomfort, this specific symptom combination triggers a cascade of organ-level consequences that justify urgent provider contact rather than waiting. Prerenal acute kidney injury: sustained vomiting and reduced oral intake → circulating blood volume drops → reduced renal afferent arteriolar pressure → juxtaglomerular cells detect reduced stretch → renin secretion → angiotensinogen → angiotensin I → ACE (angiotensin-converting enzyme) → angiotensin II (AngII) → AT1R (Gq/Gi-coupled) on efferent glomerular arterioles → efferent vasoconstriction → maintained intraglomerular pressure for a time, but reduced total renal plasma flow → GFR falls when compensatory vasoconstriction is insufficient → creatinine rises (prerenal azotemia); AngII simultaneously drives aldosterone secretion from adrenal zona glomerulosa → mineralocorticoid receptor (MR) in collecting duct principal cells → ENaC + Na⁺/K⁺-ATPase upregulation → sodium and water retention attempting to restore volume. Patients on GLP-1 drugs already have a GLP-1R/Gs/cAMP/PKA → NHE3 phosphorylation natriuretic signal reducing proximal tubule sodium reabsorption; severe dehydration reverses this through AngII-driven compensatory reabsorption that overwhelms the GLP-1/PKA/NHERF1 natriuretic signal at the NHE3 scaffolding level: AngII binds AT1R on proximal tubule cells → AT1R activates SRC kinase → SRC phosphorylates NHERF2 (Na⁺/H⁺ exchanger regulatory factor 2) → phospho-NHERF2 outcompetes NHERF1 for the C-terminal PDZ-binding motif of NHE3; NHERF1 is the scaffold through which GLP-1R/PKA drives NHE3 into subapical endosomes (NHERF1 bridges NHE3 to the ezrin-RADIXIN-moesin complex that anchors the clathrin endocytic machinery), while NHERF2 sterically blocks this internalization route and tethers NHE3 stably at the apical brush border surface; with NHERF2 displacing NHERF1, NHE3 returns to the apical membrane and actively reabsorbs Na⁺ from the tubular lumen, reversing natriuresis — but the transition is abrupt, and eGFR can drop 20–30% within 24 hours of sustained fluid loss. Hypokalemia with arrhythmia risk: vomiting removes HCl (H⁺ + Cl⁻) from the stomach → metabolic alkalosis (serum HCO₃⁻ rises as H⁺ is lost) → kidneys attempt to compensate by excreting HCO₃⁻, but this requires alkaline urine production → the renal compensation trades HCO₃⁻ excretion for K⁺ retention at first, but the volume-depleted AngII → aldosterone axis simultaneously increases ROMK channel and MR-driven K⁺ secretion into the tubular lumen → net K⁺ wasting despite overall volume contraction → hypokalemia. Hypokalemia reduces the K⁺ equilibrium potential (E_K) in cardiac myocytes → E_K becomes less negative → resting membrane potential shifts toward threshold → prolonged cardiac action potential repolarization (reduces the repolarizing IK1 and IKr currents that depend on the extracellular-intracellular K⁺ gradient) → QTc interval prolongation → conditions for early afterdepolarizations (EADs) and torsades de pointes (TdP) arrhythmia, particularly in patients on other QT-prolonging medications. Serum K⁺ below 3.0 mEq/L warrants oral or IV repletion before resuming GLP-1 therapy, and below 2.5 mEq/L requires IV treatment and cardiac monitoring
Sudden vision changes (rare worsening of diabetic retinopathy with rapid glucose lowering)
Neck lump or difficulty swallowing (thyroid C-cell precaution)

Growth Hormone Secretagogues (Sermorelin, Ipamorelin, CJC-1295, Tesamorelin)

All GH secretagogues share the same core monitoring rationale: they stimulate the GH/IGF-1 axis, which affects glucose metabolism, fluid balance, thyroid function, and cardiovascular parameters.

IGF-1: The Primary Monitoring Target

IGF-1 is the most reliable, practically accessible measure of GH axis activity.

Target: Age-adjusted normal range. The goal is not to maximize IGF-1 — it is to achieve a level consistent with healthy reference norms, not supraphysiologic elevation.
Supranormal IGF-1 (above the top of the age-matched reference range): Dose reduction or pause therapy. Sustained supranormal IGF-1 is the mechanism behind some long-term risks of GH excess.
No response (IGF-1 unchanged from baseline at 8–12 weeks): Consider product quality, dosing, timing (GH secretagogues work best at night, around natural GH pulsatility), or whether a suppressor (corticosteroids, obesity-related hypothalamic suppression) is blunting response. The obesity-related mechanism deserves specific attention because it determines whether dose escalation can improve response or whether addressing adiposity first is more mechanistically appropriate. Three converging pathways explain why significant excess visceral fat blunts GH secretagogue response. First, hyperinsulinemia-driven IGF-1 excess: visceral adiposity creates peripheral insulin resistance → compensatory pancreatic β-cell hyperinsulinemia → elevated portal insulin in hepatocytes → insulin’s PI3K/Akt pathway upregulates IGF-1 synthesis above the normally GH-controlled setpoint. The resulting elevated circulating IGF-1 crosses the blood-brain barrier via LRP1 (low-density lipoprotein receptor-related protein 1) and acts on two hypothalamic cell populations: IGF-1R/IRS-1/PI3K/Akt in periventricular somatostatin neurons → increased somatostatin synthesis and release into the hypophyseal portal circulation → SST2R/SST5R (Gi/o-coupled) on somatotrophs → adenylyl cyclase inhibition → reduced cAMP/PKA → blunted GH exocytosis even when the GHRH-R or GHSR agonist is present; and IGF-1R signaling on GHRH neurons in the arcuate nucleus → negative-feedback attenuation of GHRH pulse amplitude, reducing the native GHRH activity that secretagogues depend on amplifying. Second, visceral FFA-driven somatostatin amplification: elevated free fatty acids from visceral adipose lipolysis reach hypothalamic neurons and undergo partial β-oxidation → hypothalamic malonyl-CoA accumulates → CPT1 (carnitine palmitoyltransferase 1) is inhibited → cytoplasmic long-chain acyl-CoA species rise → these serve as nutrient surplus sensors in periventricular somatostatin neurons via two converging ion-channel mechanisms: LC-acyl-CoA directly inhibits K_ATP channels (SUR1/Kir6.2) on the periventricular somatostatin neuron membrane (LC-acyl-CoA binds the SUR1 regulatory subunit’s nucleotide-binding domains and shifts the channel toward a closed-probability-favoring conformation, removing the tonic hyperpolarizing K⁺ current that normally maintains resting membrane potential) → K_ATP closure → membrane depolarization → Cav2.2 (N-type voltage-gated Ca²⁺ channel) activation → Ca²⁺ influx → SNARE complex assembly → SST granule exocytosis; additionally, LC-acyl-CoA activates PKCδ/PKCε isoforms (diacylglycerol-independent novel PKC isoforms sensitive to acyl-CoA) → PKC phosphorylates Cav2.2 at Ser/Thr residues in the intracellular loop II-III domain → increased channel open probability per depolarization → amplified Ca²⁺ entry per action potential → greater SST secretion rate, independently of and additively to the IGF-1 mechanism. Third, sleep architecture disruption from OSA: obesity-associated obstructive sleep apnea fragments slow-wave sleep (SWS, N3/N4 stages). The nocturnal GH pulse — which contributes approximately 70% of daily GH output — is temporally coupled to N3 SWS entry through hypothalamic GHRH neuron activation during SWS transitions; OSA-related arousals interrupt SWS, attenuate the synchronized GHRH burst, and therefore reduce the native nocturnal GH pulsatility that secretagogues are designed to amplify. The monitoring implication: in an obese patient whose IGF-1 does not rise at 8–12 weeks, all three mechanisms (elevated SST from IGF-1/FFA, blunted GHRH from IGF-1 negative feedback, fragmented SWS) are operating simultaneously. Dose escalation adds more agonist to an already-suppressed system; the somatostatin brake does not lift with higher secretagogue dose. Weight loss — particularly visceral fat reduction — is mechanistically more specific: it reduces compensatory insulinemia, lowers portal IGF-1, decreases FFA-driven SST amplification, and improves SWS architecture, removing all three suppressors in parallel.

IGF-1 monitoring schedule: Baseline → 8–12 weeks → every 6 months once stable.

Glucose and Insulin Sensitivity

Fasting glucose at baseline and every 3–6 months
HbA1c at baseline and every 6 months
GH is insulin-counterregulatory through two parallel molecular mechanisms. First, the GHR/JAK2/STAT5b transcriptional response upregulates SOCS1, SOCS2, and SOCS3 (suppressor of cytokine signaling proteins). The SH2 domain of SOCS proteins docks onto phosphotyrosine sites on IRS-1 (insulin receptor substrate 1), physically occluding IRS-1’s engagement with the insulin receptor activation loop — the same IRS-1/PI3K/Akt pathway that normally drives GLUT4 translocation to the plasma membrane in skeletal muscle and adipose tissue. The SOCS-box domain simultaneously recruits an Elongin-B/C/Cullin-5/RBX2 E3 ubiquitin ligase complex that polyubiquitinates IRS-1 at multiple lysine residues, targeting it for 26S proteasomal degradation — reducing steady-state IRS-1 protein levels and sustaining insulin resistance for hours beyond the duration of the GH pulse itself. Second, STAT5b drives hepatic transcriptional upregulation of PEPCK (phosphoenolpyruvate carboxykinase, PCK1) and glucose-6-phosphatase (G6PC) → increased gluconeogenic flux from amino acid and lactate precursors and accelerated glycogen-to-glucose conversion → elevated fasting hepatic glucose output. The fasting glucose elevation is specifically the PEPCK/G6PC mechanism at work between meals; the post-prandial glucose elevation reflects the SOCS-mediated peripheral GLUT4 suppression. Both mechanisms operate simultaneously and independently. Patients with pre-existing insulin resistance have reduced baseline IRS-1/PI3K/Akt reserve, making SOCS-driven IRS-1 degradation disproportionately consequential — a partial reduction in IRS-1 protein in an already-resistant system produces a larger absolute glucose rise than the same reduction in an insulin-sensitive patient. The tesamorelin FDA approval data confirmed this glucose-raising effect at therapeutic doses. A rise from below 5.7% to the pre-diabetes HbA1c range (5.7–6.4%) during GH secretagogue therapy warrants dose reduction discussion with your provider rather than simply continued monitoring at the same interval.

Thyroid Function

TSH and free T4 at baseline and every 6–12 months; add free T3 if you are on levothyroxine monotherapy

The mechanism matters here: GH upregulates type 1 5’-deiodinase (D1) — the enzyme responsible for converting the inactive thyroid prohormone T4 to active T3 in peripheral tissues (liver, kidney, muscle). Optimizing GH axis output through secretagogues therefore increases T4-to-T3 conversion, which can meaningfully elevate free T3 in patients who are stable on a levothyroxine dose.

The molecular pathway by which GH increases D1 expression is now well characterized: GH binds the growth hormone receptor (GHR) on hepatocytes and other peripheral cells → GHR homodimerizes → constitutively associated JAK2 undergoes transautophosphorylation → activated JAK2 phosphorylates STAT5b at Tyr699 → phospho-STAT5b dimerizes → the dimer translocates to the nucleus and binds gamma-activated sequence (GAS) elements in the 5’-regulatory region of the DIO1 gene (encoding type 1 5’-deiodinase) → increased DIO1 transcription → more D1 enzyme protein in liver and kidney → greater T4-to-T3 conversion throughput (Darras et al., PMID:9851770; Peeters et al., PMID:16099826). This is the same JAK2-STAT5b axis that governs IGF-1 transcription in the liver, so the D1 effect tracks closely with IGF-1 response — a patient whose IGF-1 is rising in response to a GH secretagogue is also increasing peripheral T4-to-T3 conversion through the same signaling node.

In practice, this means patients on levothyroxine who start a GH secretagogue may find that their existing T4 dose now produces more T3 than before — potentially causing symptoms of mild thyroid hormone excess (palpitations, anxiety, heat intolerance, insomnia) even though their TSH and levothyroxine dose haven’t changed. Adding free T3 to the monitoring panel at the 8–12 week mark is appropriate for this group.

Conversely, untreated or undertreated hypothyroidism suppresses GH secretagogue response by reducing the downstream signaling sensitivity of the GH axis. Optimizing thyroid status (TSH in the 1–2 mU/L range rather than the 4–5 range) before starting a GH secretagogue often improves response.

The molecular basis for this suppression operates through two convergent mechanisms. First, triiodothyronine (T3) directly regulates the transcription of the GHRH receptor (GHRHR) in pituitary somatotrophs through thyroid hormone response elements (TREs) in the GHRHR gene promoter. In the euthyroid state: free T3 diffuses into the nucleus of pituitary somatotrophs → binds thyroid hormone receptor β1 (TRβ1), which heterodimerizes with the retinoid X receptor (RXR) → the TRβ1/RXR heterodimer occupies TRE half-sites in the GHRHR proximal promoter → recruits the TRAP/DRIP mediator complex and p300/CBP coactivators → H3K27ac at the GHRHR locus → active GHRHR transcription → higher GHRHR surface density on somatotroph plasma membranes → greater Gs-coupled cAMP generation per GHRH stimulus → larger Ca²⁺ transient → larger GH exocytic pulse. In hypothyroidism, reduced free T3 means TRβ1/RXR occupies TREs as a repressor complex (unliganded TR recruits NCoR/SMRT corepressors and HDACs) → GHRHR transcription is actively suppressed below basal → somatotrophs display fewer receptors → blunted GH pulse amplitude in response to exogenous GHRH analogues (sermorelin, CJC-1295) and to GHSR agonists (ipamorelin, GHRP-2) that must ultimately amplify GHRH-driven pulses or signal through diminished downstream cAMP reserves.

Second, hypothyroidism elevates periventricular nucleus (PeVN) somatostatin (SST) tone. In the euthyroid state, T3 modestly suppresses SST gene transcription in PeVN neurons through negative TREs; in hypothyroidism this braking is removed → increased SST synthesis and release into hypophyseal portal blood → SSTR2 and SSTR5 on somatotroph plasma membranes → Gαi/o → adenylyl cyclase inhibition → reduced cAMP/PKA → PKA-mediated phosphorylation of VGCC (voltage-gated Ca²⁺ channel) complexes is attenuated → smaller Ca²⁺ transients during each GH-secretagogue-induced AP burst → less GH vesicle fusion per stimulus pulse. SST also activates GIRK (Kir3.x) channels via Gβγ → membrane hyperpolarization → raises the AP threshold the secretagogue must overcome. The net result of both mechanisms — fewer GHRHR receptors and a higher SST inhibitory brake — means that a hypothyroid patient given the same ipamorelin or sermorelin dose as a euthyroid patient will generate substantially lower peak and mean GH output, which translates directly into a blunted IGF-1 rise and a clinically non-responsive picture. Correcting TSH toward 1–2 mU/L reverses both mechanisms: GHRHR expression recovers over weeks as T3 relieves NCoR/SMRT-mediated repression, and PeVN SST tone returns to baseline.

PSA Monitoring for Men on GH Secretagogues

Prostate-specific antigen (PSA) monitoring deserves explicit discussion for men on GH secretagogue therapy. IGF-1 — which GH secretagogues elevate — is a known mitogen for prostate tissue. Epidemiological studies have found associations between higher circulating IGF-1 levels and increased prostate cancer risk (Renehan et al., 2004, PMID:15110491). The Chan et al. 1998 Physicians’ Health Study found that men in the highest IGF-1 quartile had approximately 2.4-fold increased prostate cancer risk compared to the lowest quartile.

This does not mean GH secretagogues cause prostate cancer. The epidemiological association is with naturally elevated IGF-1, not pharmacologically modulated IGF-1, and causality has not been established. However, it is a biologically plausible concern that warrants proactive monitoring.

Practical PSA protocol for men on GH secretagogues:

Situation	Recommendation
Men under 40 on GH secretagogue	Baseline PSA at start of therapy; recheck annually
Men 40–50 on GH secretagogue	Baseline PSA; recheck every 6–12 months
Men over 50 on GH secretagogue	Baseline PSA; recheck every 6 months (earlier and more frequent than standard screening)
Any man with elevated or rising PSA	Hold or reduce GH secretagogue dose; refer to urology before restarting

PSA velocity (rate of change) is as important as absolute value. A PSA that rises from 0.8 to 1.6 ng/mL over 12 months is more concerning than a stable PSA of 2.0 ng/mL. A rise greater than 0.75 ng/mL per year is the clinical threshold for triggering urological evaluation regardless of absolute PSA level. The mechanistic reason velocity outperforms absolute PSA for cancer detection relates to the biology of PSA production and the difference in growth kinetics between prostate cancer and benign prostatic hyperplasia (BPH). PSA (kallikrein-related peptidase 3, KLK3) is transcribed in prostate epithelial cells under direct androgen receptor (AR) control: AR binds testosterone/DHT → AR translocates to the nucleus → binds androgen response elements (AREs) in the KLK3 promoter → drives KLK3/PSA mRNA transcription. PSA is therefore a direct readout of AR-active prostate epithelial cell mass. In BPH, prostate volume increases slowly through hyperplasia of benign AR-positive glandular cells — a process that adds PSA-producing cells approximately linearly over years, producing PSA increases that are slow and consistent (typically <0.4 ng/mL/year). In prostate cancer, malignant cells frequently harbor AR amplification, constitutively active AR splice variants (AR-V7, AR-V3), or activating AR mutations that sustain transcription independent of ligand — plus Akt/mTOR-driven proliferative signaling that accelerates cell doubling time. The result is an exponential cell growth kinetic: each doubling event doubles the PSA-producing cell population. The transition from BPH-like linear growth to cancer-like exponential growth is what crosses the 0.75 ng/mL/year threshold — exponentially growing prostate cancer cells produce PSA velocity inconsistent with the slow, linear glandular expansion of BPH. Additionally, the AR/KLK3 axis in malignant cells is less subject to the normal paracrine negative feedback from adjacent stromal cells that limits benign PSA output, meaning cancerous tissue produces proportionally more PSA per gram than benign tissue. These combined factors — exponential growth kinetics, AR amplification/constitutive activity, and reduced paracrine inhibition — are why a PSA velocity above 0.75 ng/mL/year is considered a flag for pathological prostate AR activity regardless of absolute PSA level.

A stable PSA within normal range during GH secretagogue therapy with IGF-1 maintained in the normal (not supranormal) range does not require suspension of therapy — it represents appropriate monitoring of a known theoretical risk.

Why the IGF-1/cancer biology warrants this precaution: The epidemiological association between elevated IGF-1 and increased cancer risk reflects specific receptor-level mitogenic biology rather than coincidence:

IGF-1R → PI3K/Akt/mTOR — with p53 suppression as the cancer-critical arm: The IGF-1 receptor (IGF-1R) activates the PI3K → Akt → mTOR proliferation and survival cascade — the same pathway found constitutively activated in a large proportion of human cancers via somatic PIK3CA, PTEN, and AKT mutations. The mechanistic link to cancer risk is most specific in the Akt → MDM2 → p53 axis: Akt phosphorylates MDM2 (mouse double minute 2 oncoprotein) at Ser166/Ser186, activating MDM2 and driving its nuclear localization. In the nucleus, active MDM2 functions as an E3 ubiquitin ligase that mono- and polyubiquitinates p53 at Lys370/372/373/381/382 → nuclear export of ubiquitinated p53 → cytoplasmic proteasomal degradation → p53 protein levels drop. p53 is the “guardian of the genome” — it normally responds to DNA damage (strand breaks, oxidative lesions, replication errors) by transcriptionally activating p21/CDKN1A (cell cycle arrest), PUMA/BBC3 (pro-apoptotic, BH3-only protein → Bax activation → MOMP → caspase-9/3 → apoptosis), and GADD45 (DNA repair). When IGF-1/Akt-driven MDM2 degrades p53, these checkpoints are disabled: cells with pre-malignant DNA damage that would normally trigger p53-dependent apoptosis or permanent arrest instead survive and continue dividing. This is not cancer de novo from normal IGF-1 — it is permissive survival of cells that already harbor damage (LeRoith & Roberts, 2003, PMID:12963990). The clinical monitoring implication is specific: maintaining IGF-1 within the age-matched normal range (not supranormal) bounds the degree of MDM2 activation and p53 suppression, preserving normal genome surveillance in tissues that accumulate mutations over a lifetime of cellular division.
IGFBP-3 depletion: IGFBP-3, the primary circulating carrier protein for IGF-1, has independent pro-apoptotic activity in some cell types beyond its carrier function. High circulating IGF-1 stimulates IGFBP-3 clearance, which may reduce this anti-proliferative effect in target tissues. The clearance mechanism operates through PAPP-A (pregnancy-associated plasma protein A) — a zinc metalloprotease transcriptionally upregulated by IGF-1 itself in vascular smooth muscle cells, fibroblasts, and granulosa cells via the IGF-1R/PI3K/Akt/mTORC1 → AP-1 (c-Jun/c-Fos) → TRE (phorbol-ester response element) sites in the PAPPA gene promoter. Secreted PAPP-A cleaves IGFBP-3 and IGFBP-5 at specific Ser-His protease sites, releasing previously carrier-bound IGF-1 into the free, biologically active fraction. This creates a feed-forward amplification loop: elevated IGF-1 → more PAPP-A → more IGFBP-3 cleavage → more free IGF-1 bioavailable in tissues — meaning effective IGF-1 receptor occupancy at target tissues is higher than total serum IGF-1 measurements indicate when PAPP-A is upregulated. In the cancer biology context, PAPP-A-driven IGFBP-3 cleavage compounds the risk: the Akt/MDM2/p53 surveillance disruption described above operates on higher effective free IGF-1, while simultaneously the intact IGFBP-3 that would otherwise attenuate IGF-1 bioavailability is depleted. The independent anti-proliferative activity of intact IGFBP-3 operates through two structural pathways separate from its IGF-1 carrier function. First, nuclear import: intact IGFBP-3 contains a nuclear localization sequence in its C-terminal domain; it is internalized by cells via megalin/LRP2 (a multi-ligand endocytic receptor on many epithelial cells) or through importin-β interaction → transported to the nucleus → binds RXRα (retinoid X receptor alpha) through its N-terminal domain → the IGFBP-3/RXRα complex acts at retinoic acid response element (RARE)-containing promoters of pro-apoptotic genes → drives caspase-activating factor expression independently of IGF-1 binding. Second, cell-surface signaling: intact IGFBP-3 binds a TGF-β type V receptor (TβRV) on the plasma membrane → activates ceramide generation → PKCζ → SAPK/JNK activation → pro-apoptotic downstream signaling. PAPP-A cleavage of IGFBP-3 simultaneously eliminates both the nuclear RXRα pathway and the surface TβRV pathway, removing two anti-proliferative inputs at the same time as it releases bioavailable IGF-1 — explaining why IGFBP-3 fragmentation is a specific adverse signal beyond simply reflecting high IGF-1. The monitoring implication reinforces maintaining IGF-1 within — not above — the age-matched normal range: supranormal IGF-1 drives PAPP-A-mediated IGFBP-3 degradation, compounding the Akt/MDM2/p53 surveillance reduction with dual loss of IGFBP-3’s independent anti-proliferative nuclear and membrane signaling.

The practical implication for GH secretagogue users is not that therapeutic-range IGF-1 causes cancer de novo. It is that persistently supranormal IGF-1 creates a permissive mitogenic environment that could accelerate growth of pre-malignant cells that already exist. This is the biological rationale for the therapeutic target of maintaining IGF-1 within — not above — the age-matched normal range, rather than seeking to maximize it.

Men with a personal history of prostate cancer should discuss GH secretagogue use specifically with their oncologist before starting; IGF-1 optimization is generally considered contraindicated with active prostate malignancy.

Fluid Retention

Blood pressure at each monitoring visit
Assess for peripheral edema (ankle swelling, ring tightness, carpal tunnel-like symptoms)
GH promotes sodium and water retention through a direct renal tubular mechanism. The molecular pathway: GH → GHR → JAK2/STAT5b → hepatic IGF-1 production → circulating IGF-1 → IGF-1R on proximal convoluted tubule cells → IRS-1/PI3K/Akt → Akt phosphorylates and increases expression of Na⁺/K⁺-ATPase at the basolateral membrane of proximal tubule cells, increasing active sodium reabsorption from the tubular lumen. GH also directly upregulates ENaC (epithelial sodium channel) expression in the cortical collecting duct through a STAT5b-mediated transcriptional pathway independent of IGF-1; ENaC-mediated sodium entry at the apical membrane of collecting duct principal cells is the primary site of aldosterone action, and GH effectively mimics a subset of aldosterone’s sodium-retaining effects through ENaC upregulation. The retained sodium creates an osmotic gradient → water follows passively via aquaporin channels → net fluid volume expansion → increased blood pressure and interstitial fluid accumulation (edema). Carpal tunnel symptoms at GH-excess doses reflect fluid accumulation within the carpal tunnel compressing the median nerve — the same mechanism seen in acromegaly. This effect is dose-related and usually mild at therapeutic IGF-1-normal doses but can worsen hypertension in susceptible patients and warrants serial blood pressure monitoring.

Monitoring Schedule Summary for GH Secretagogues

Lab	Baseline	8–12 weeks	6 months	Annually
IGF-1	✓	✓	✓	✓
Fasting glucose	✓	✓	✓	✓
HbA1c	✓		✓	✓
Thyroid (TSH/fT4)	✓		✓	✓
Lipid panel	✓		✓	✓
Blood pressure	✓	✓	✓	✓
CMP (kidney/liver)	✓		✓	✓

PT-141 / Bremelanotide (Vyleesi)

PT-141 is used acutely (per-dose) rather than chronically, so its monitoring profile is simpler and focused on the period around each use.

Blood Pressure Monitoring

Baseline before first use
Home blood pressure measurement before each dose and 2–4 hours after dose for the first several uses
PT-141 consistently elevates blood pressure — documented in RECONNECT FDA approval trials. The Vyleesi prescribing information warns against use in patients with uncontrolled hypertension or known cardiovascular disease. The mechanism is central, not peripheral. While PT-141’s sexual arousal effects are mediated by MC4R in the medial preoptic area (MPOA), the blood pressure elevation originates from MC4R in the paraventricular nucleus (PVN) and spinal cord — anatomically distinct MC4R populations with different output circuitry. PVN neurons expressing MC4R project to the rostral ventrolateral medulla (RVLM), the primary brainstem cardiovascular control center. PT-141 → MC4R/Gαs/cAMP/PKA in PVN neurons → increased PVN excitatory output to RVLM → RVLM neurons activate spinal sympathetic preganglionic neurons in the intermediolateral cell column (IML) of the thoracolumbar spinal cord → increased sympathetic efferent discharge to cardiovascular targets through two parallel arms: (1) α1-adrenergic (vasoconstrictor) arm: sympathetic postganglionic norepinephrine (NE) release at α1-AR on arteriolar smooth muscle → α1-AR/Gq/PLC-β/IP₃/Ca²⁺ → smooth muscle contraction → increased peripheral vascular resistance → systolic and diastolic BP elevation; (2) β1-adrenergic (cardiac) arm: NE release at β1-AR on SA node and ventricular myocardium → β1-AR/Gs/cAMP/PKA → positive chronotropy (HCN4 phosphorylation → increased spontaneous heart rate) and positive inotropy (phospholamban phosphorylation → increased sarcoplasmic reticulum Ca²⁺ load → stronger contraction) → increased cardiac output → additional BP elevation. MC4R expressed on spinal IML preganglionic neurons also responds directly to PT-141 → provides a second, RVLM-independent sympathoexcitatory input. This mechanistic separation explains why PT-141’s blood pressure effect occurs alongside — not because of — its arousal effects: the MPOA (arousal) and PVN/spinal (sympathetic/BP) MC4R populations are driven simultaneously by systemic peptide exposure but produce completely different physiological outputs.

What to watch for: A rise of more than 20 mmHg systolic or 10 mmHg diastolic above your baseline warrants discussion with your provider. Any reading above 160/100 after PT-141 warrants same-day provider contact.

Patient with controlled hypertension on medications: Discuss explicitly with your prescribing physician whether the transient BP elevation is acceptable given your current medication regimen and baseline readings.

Pigmentation Changes

Visual self-assessment: new or darkening moles or skin lesions, changes in gum pigmentation
PT-141 acts on MC1R (melanocortin-1 receptor) in addition to the MC4R responsible for its central effects, increasing melanin production. Hyperpigmentation of the face, gums, and breasts is documented.
The FDA labeling recommends no more than 8 doses per month partly to limit cumulative pigmentation effects.
New or changing pigmented lesions should be evaluated by a dermatologist to distinguish benign hyperpigmentation from pathological changes.

Why MC1R activation causes pigmentation: the melanogenesis pathway. MC1R is a Gs-coupled receptor expressed on melanocytes — the pigment-producing cells in the skin, hair follicles, and mucosal tissues. When bremelanotide (PT-141) binds MC1R → Gs → adenylyl cyclase → cAMP → PKA activation. PKA phosphorylates MITF (microphthalmia-associated transcription factor), the master regulator of melanocyte biology. Phosphorylated MITF binds M-box promoter elements on melanogenic enzyme genes, upregulating transcription of TYR (tyrosinase), TYRP1 (tyrosinase-related protein 1), and DCT (dopachrome tautomerase). These enzymes work in sequence: tyrosinase catalyzes the rate-limiting step — hydroxylation of tyrosine to DOPA, then oxidation of DOPA to dopaquinone. Dopaquinone is then polymerized (via TYRP1/DCT-catalyzed intermediate steps) into eumelanin (brown-black) or, if cysteine is present, pheomelanin (red-yellow). The resulting melanin is packaged into melanosomes and transferred from melanocytes to surrounding keratinocytes via dendritic extensions — producing visible skin darkening.

This pathway explains both the anatomical pattern and the dose-dependence of PT-141-associated pigmentation: mucosal tissues (gums, areolae) are rich in MC1R-expressing melanocytes and show pigmentation first; the effect is proportional to cumulative melanocortin receptor activation and is largely reversible over months after discontinuation as pigmented keratinocytes turn over. The 8-dose/month limit in the FDA label is not arbitrary — it reflects the observation in approval trials that pigmentation accumulation was dose-related and time-related, and limiting monthly exposure bounds cumulative MITF activation in melanocytes.

BPC-157 and TB-500 / Thymosin Beta-4

These compounds do not have approved monitoring protocols because they are not approved drugs and have not completed human clinical trials. Established specific monitoring guidance does not exist.

Practical minimum:

Baseline CMP (kidney and liver function) and CBC before starting
Repeat CMP and CBC at 3–6 months during chronic use
Monitor injection sites for unusual reactions (induration, persistent pain, spreading redness, warmth)
Report any unexpected symptom changes (new inflammatory symptoms, unusual fatigue, GI changes) to a provider without waiting for the next scheduled visit
For patients with cancer history considering TB-500: discuss with your oncologist before starting; Thymosin Beta-4 upregulation has been documented in some cancer cell lines, and the mechanistic basis for this concern is specific enough to warrant pathway-level consideration. Tβ4 signals primarily through integrin-linked kinase (ILK), a scaffold kinase that bridges ECM-integrin engagement to cytoplasmic signaling. ILK phosphorylates Akt at Ser473 (the hydrophobic motif site, distinct from PDK1’s Thr308 phosphorylation), producing fully activated Akt. Active Akt then phosphorylates GSK-3β at Ser9, sterically inactivating it. GSK-3β is the constitutive kinase in the β-catenin destruction complex (GSK-3β/CK1/APC/Axin); its inactivation prevents the Ser33/Ser37/Thr41/Ser45 phosphorylation cascade that recruits the β-TrCP E3 ubiquitin ligase. β-catenin therefore escapes proteasomal degradation, accumulates in the cytoplasm, and translocates to the nucleus where it binds TCF/LEF transcription factors and drives expression of VEGF-A (promoting tumor angiogenesis), MMP-2 (enabling basement membrane invasion), cyclin D1, and c-Myc. Critically, the ILK/Akt/β-catenin axis is the same pathway constitutively activated in multiple cancer types via gain-of-function PIK3CA mutations (p110α → phosphatidylinositol-3,4,5-trisphosphate → PDK1/Akt), PTEN loss (removes the phosphatase that opposes PI3K), and activating CTNNB1 mutations (β-catenin Ser/Thr → Ala substitutions that directly prevent GSK-3β phosphorylation). Exogenous Tβ4 layering on top of a cancer biology that already has partial activation of this pathway represents a mechanistically coherent — not speculative — concern, which is why oncology consultation must address not just angiogenesis generally but the specific PI3K/Akt/Wnt/β-catenin status of the patient’s prior tumor

The lack of established monitoring guidance is itself a signal — it reflects the absence of human trial data, not established safety at any particular monitoring interval.

GHK-Cu (Injectable / Systemic)

Topical GHK-Cu (cosmetic formulations) requires no lab monitoring. For injectable GHK-Cu:

Baseline CMP including kidney and liver function
Serum copper levels at baseline if using chronically — to document copper status before adding a copper-containing compound
Repeat copper, CMP at 3–6 months during chronic use
Patients with conditions affecting copper metabolism (Wilson’s disease, primary biliary cirrhosis) should not use injectable GHK-Cu without specific specialist guidance

The systemic injectable evidence base for GHK-Cu is preclinical; the monitoring recommendations above represent general prudence for an injectable compound rather than compound-specific evidence-based guidance.

Thymosin Alpha-1

For viral hepatitis (HBV, HCV): Your hepatologist or infectious disease specialist manages monitoring. Standard hepatitis monitoring applies: liver enzymes (ALT, AST, GGT), HBV DNA viral load, HBeAg/anti-HBe status, liver function tests. Intervals are determined by the treating physician based on treatment goals and response.

Why HBeAg/anti-HBe seroconversion is the mechanistically specific target for Tα1 in hepatitis B: HBV immune clearance depends on CD8+ cytotoxic T lymphocytes (CTLs) recognizing HBcAg peptides presented on HLA class I → CTL-mediated lysis of infected hepatocytes and non-cytolytic IFN-γ/IFN-α secretion that suppresses intracellular HBV replication. However, HBeAg — a secreted, non-structural isoform of the core antigen generated from a longer precore mRNA — functions as a systemic immunological tolerogen: high circulating HBeAg concentrations actively suppress HBcAg-specific CD4+ T-helper and CD8+ CTL responses through PD-1/LAG-3-driven T-cell exhaustion in chronic infection, creating the immunological stalemate that allows HBV to persist for decades. The therapeutic goal in HBeAg-positive chronic HBV is therefore to reduce viral replication sufficiently that circulating HBeAg concentrations fall → the HBeAg-maintained peripheral tolerance is withdrawn → HBcAg/HBeAg-specific T-cell effector responses emerge and consolidate → HBeAg seroconversion occurs (HBeAg disappears from serum; anti-HBe antibody appears) → sustained virological remission follows. Tα1 supports this trajectory through its TH1-polarizing effects — promoting functional CD8+ CTL responses against HBcAg/HBeAg peptide epitopes — and through its thymus-mediated TdT/TCR diversity expansion that broadens the naive T-cell pool’s capacity to mount de novo HBV-specific responses. HBeAg/anti-HBe status is not generic immune surveillance: it is the direct readout of whether Tα1’s immunological mechanism is translating into the viral antigen reduction and immune reconstitution that define clinical response (Andreone et al., PMID:9581985).

For immune support contexts: Baseline CBC with differential to document immune cell populations. Periodic CBC during treatment. Serum immunoglobulin levels (IgG, IgA, IgM) at baseline if immune deficiency is the indication.

The reason these specific labs — and not, for example, a broader cytokine panel — are the practical monitoring targets for Tα1 immune support is that they directly read out the cell populations and protein products most affected by Tα1’s primary mechanism.

Tα1’s immunostimulatory effect operates through TH1 polarization of the adaptive immune response: Tα1 binds TLR2/4 on dendritic cells and macrophages → MyD88 → NF-κB → IL-12p70 production; IL-12p70 drives STAT4 phosphorylation in naive CD4+ T-helper cells → STAT4 → T-bet transcription factor expression → T-bet drives IFN-γ production and suppresses GATA-3 (the TH2 master regulator) → the CD4+ pool shifts toward IFN-γ-producing TH1 effectors. Tα1 additionally promotes NK cell and CD8+ cytotoxic T-lymphocyte (CTL) maturation directly: thymalin-like signaling → TdT (terminal deoxynucleotidyl transferase) expression in thymic precursors → broader TCR diversity in the naive T-cell output → improved antigen-specific CD8+ CTL response amplitude. Both NK cells and CD8+ T-cells express the surface markers distinguishable on a CBC with differential: NK cells (CD3⁻CD56⁺) and cytotoxic lymphocytes contribute to the total lymphocyte count and lymphocyte-to-neutrophil ratio. In patients using Tα1 for immune support, progressive improvement in total lymphocyte count and normalization of a previously inverted lymphocyte ratio provides the most accessible proxy for whether the TH1/NK/CTL axis is responding — without requiring the more expensive flow cytometry panel that would directly count CD56+ and CD8+ populations.

Immunoglobulin monitoring reads the downstream B-cell output of TH1 skewing. B cells require both antigen encounter and T-helper co-stimulation for class-switch recombination. Under TH1-dominated conditions (IL-12/IFN-γ predominant, minimal IL-4/IL-13 from TH2): IFN-γ binds IFN-γR on B cells → JAK1/2-STAT1 → upregulates AID (activation-induced cytidine deaminase) specifically toward IgG1 and IgG3 class switch targets in the IGHG1/IGHG3 switch regions. IL-4 from TH2 cells drives IgE switching through a different AID-binding site; without TH2 IL-4, IgE switching is suppressed. Serial IgG monitoring therefore documents whether Tα1-driven TH1 polarization is producing the protective immunoglobulin subclass most relevant to bacterial opsonization and viral neutralization — the immune effector function that matters in most immune support contexts. Baseline IgG below the lower limit of normal identifies patients with B-cell class-switch recombination impairment or pre-existing hypogammaglobulinemia who may need IVIG supplementation in addition to Tα1, rather than Tα1 alone. Serial IgG rising toward the normal range during Tα1 therapy provides molecular evidence of improved TH1-driven humoral immunity — the same class-switch mechanism that distinguishes Tα1’s mechanism from non-specific immunostimulants that increase cellular counts without improving functional antibody class output.

Combination Peptide Monitoring: When Multiple Compounds Are Used

Some patients use more than one peptide concurrently — for example, ipamorelin/CJC-1295 with BPC-157, or a GLP-1 medication with a GH secretagogue. The monitoring requirements compound.

Key interactions to watch for:

GH secretagogue + GLP-1 drug: GH raises glucose through two molecular mechanisms that are additive: (1) GH → GHR/JAK2/STAT5b → hepatic transcriptional upregulation of SOCS1/SOCS2/SOCS3 (suppressor of cytokine signaling proteins) → SOCS proteins physically bind the insulin receptor (IR) substrate IRS-1 at phosphotyrosine docking sites AND act as E3 ubiquitin ligase adaptors targeting IRS-1 for proteasomal degradation → blunted IRS-1/PI3K/Akt signaling in skeletal muscle and adipose tissue → reduced GLUT4 translocation to the plasma membrane → peripheral insulin resistance; (2) GH → hepatic transcriptional upregulation of PEPCK (phosphoenolpyruvate carboxykinase, PCK1) and glucose-6-phosphatase (G6PC) via STAT5b-driven transcription → increased gluconeogenesis and glycogen-to-glucose release → elevated fasting hepatic glucose output. GLP-1 lowers glucose by stimulating glucose-dependent insulin secretion and suppressing glucagon. These opposing actions on glucose can partially offset each other, but the glycemic balance is unpredictable in individual patients — particularly those with any degree of insulin resistance at baseline, where GH’s SOCS-mediated worsening of insulin sensitivity is not adequately compensated. HbA1c and fasting glucose at 6-week intervals during the first 6 months.
Multiple injectable compounds: Each injection site needs monitoring for local reactions. Track which sites you are using and rotate systematically to prevent local tissue changes.
Compounds affecting fluid balance: GH secretagogues retain fluid; GLP-1 drugs may cause some dehydration through reduced intake. The molecular basis for why the net balance varies by patient lies in where these two opposing signals act within the nephron. GH-driven fluid retention operates through two tubular segments that are anatomically separated: at the proximal tubule basolateral membrane, GH → GHR/JAK2/STAT5b → hepatic IGF-1 → circulating IGF-1 → IGF-1R/IRS-1/PI3K/Akt on proximal tubule cells → Na⁺/K⁺-ATPase upregulation (as detailed in the GH secretagogue fluid retention section above); and at the cortical collecting duct, GH/STAT5b drives ENaC transcriptional upregulation in principal cells, increasing apical sodium entry at the same segment where aldosterone exerts its primary action. GLP-1 receptor-mediated natriuresis operates through a single tubular target: GLP-1R/Gs/cAMP/PKA → NHE3 Ser552/Ser605 phosphorylation → NHERF1/Ezrin scaffolding disruption → NHE3 internalization into subapical endosomes → reduced apical Na⁺/H⁺ exchange at the proximal convoluted tubule only. The consequence of this anatomical segregation is that GLP-1’s natriuretic signal and GH’s proximal tubule retention signal partially compete at the proximal tubule — GLP-1 reduces luminal Na⁺ entry via NHE3 while GH increases basolateral Na⁺ exit via Na⁺/K⁺-ATPase — but GLP-1R signaling has no direct action on ENaC at the collecting duct, leaving GH’s downstream retention arm at that segment functionally uncontested by GLP-1 pharmacology. ENaC expression and activity in the collecting duct are instead governed by aldosterone, which in turn depends on RAAS activity. In patients with robust GLP-1-driven weight loss → significant visceral fat reduction → reduced adipose-derived angiotensinogen and ACE output (the mechanism underlying the FLOW trial renoprotection, described above) → lower circulating angiotensin II → reduced aldosterone secretion from the adrenal zona glomerulosa → less aldosterone-driven ENaC upregulation → GH’s collecting duct retention arm is progressively attenuated as weight loss accrues. In patients with minimal GLP-1 weight response, pre-existing elevated RAAS activity, or high baseline aldosterone tone, the ENaC segment remains aldosterone-supported and GH-enhanced; GLP-1 natriuresis at the proximal tubule cannot adequately offset this, producing net fluid retention that manifests as rising blood pressure. This nephron-segment segregation — where GLP-1 opposes GH at the proximal tubule but not the collecting duct — explains both why the net balance is individually unpredictable and why blood pressure and kidney function monitoring become the practical arbiters of which physiological program is dominating in a given patient on combination therapy.

There is no validated combination monitoring protocol in the literature — this is an area where provider individualization based on your specific compounds, medical history, and observed responses is essential.

Decision Criteria: Continue, Adjust, or Stop

Knowing when to make a change based on lab results is as important as knowing what to measure. General guidance:

Consider dose reduction or pause:

IGF-1 above age-matched upper limit of normal on GH secretagogue
HbA1c rising by ≥0.3% from baseline on GH secretagogue without prior diabetes
Blood pressure consistently above 140/90 on any protocol
eGFR declining by ≥20% from baseline without other explanation

Consider stopping therapy:

Persistent supranormal IGF-1 that does not normalize with dose reduction
New or worsening significant metabolic abnormality that does not resolve with dose adjustment
Any serious adverse event (pancreatitis, severe allergic reaction, significant cardiovascular event)
Change in cancer status — active cancer is generally a contraindication for GH secretagogues and requires reassessment for other compounds

Signs that the therapy is working (positive response indicators):

IGF-1 moving from below normal into the normal range within 8–12 weeks (GH secretagogues)
HbA1c declining 0.5% or more from baseline at 3 months (GLP-1 drugs)
Body composition improving (fat mass decreasing, lean mass stable) on DEXA
Subjective improvement in stated goals (energy, body composition, recovery, sexual health) alongside objective markers

Home Monitoring Tools Worth Having

Blood pressure cuff: A validated home blood pressure cuff ($30–50) is useful for anyone on GLP-1 drugs, PT-141, or GH secretagogues. Upper-arm automated cuffs are more accurate than wrist cuffs. Take readings in the morning before medication, after 5 minutes of sitting quietly, and record them consistently.

Continuous glucose monitor (CGM): Now available without prescription (Dexcom G7, Abbott Libre 2). For patients on GLP-1 drugs who are also on insulin or sulfonylureas, CGM provides continuous hypoglycemia detection that intermittent fingerstick testing misses. Increasingly used by non-diabetic patients on GH secretagogues who want real-time glucose data during dose changes.

Symptom and injection log: A simple notes app log of injection reactions, energy levels, sleep quality, and any symptoms that feel different from baseline is more useful than it seems over weeks of therapy. Pattern recognition from a log is far more reliable than memory.

When to Contact Your Provider Without Waiting

These symptoms warrant same-day or urgent contact regardless of where you are in the monitoring schedule:

Severe abdominal pain (possible pancreatitis with GLP-1 drugs)
Inability to keep fluids down for more than 24 hours (dehydration risk)
Blood pressure over 160/100 or symptoms of very low BP (fainting, severe dizziness)
Chest pain or palpitations
Significant injection site reaction: spreading redness, warmth, pus, or fever
Sudden vision changes
New or rapidly changing skin lesions
Fever above 38.5°C / 101.3°F with any injectable compound use

Monitoring is the difference between using a pharmacologically active compound with informed oversight and using it blind. For compounds that went through FDA approval — GLP-1 drugs, tesamorelin — the monitoring requirements are embedded in the prescribing information for a reason. For compounded peptides without that infrastructure, the responsibility falls on the prescribing provider — and on you, as an informed patient, to ask whether a monitoring plan exists and to follow it.

References

Renehan AG, Zwahlen M, Minder C, et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk. Lancet. 2004;363(9418):1346-53. PMID: 15110491
Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. PMID: 33567185
Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109-121. PMID: 38587991
Stanley TL, Falutz J, Mamputu JC, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV. AIDS. 2018;32(2):241-251. PMID: 28700011
Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141(1):150-6. PMID: 21685390

What Labs to Monitor on Peptide Therapy: A Practical Guide by Compound

Universal Baseline: Before Starting Any Peptide Therapy

How to Get Labs: Clinical vs. Direct-to-Consumer Options

Reading Results: What the Numbers Mean

IGF-1 Interpretation

HbA1c Interpretation

Kidney Function (eGFR) Interpretation

GLP-1 Receptor Agonists (Semaglutide, Tirzepatide, Liraglutide)

What to Monitor and When

GLP-1 Monitoring Schedule

Red-Flag Symptoms That Warrant Immediate Contact

Growth Hormone Secretagogues (Sermorelin, Ipamorelin, CJC-1295, Tesamorelin)

IGF-1: The Primary Monitoring Target

Glucose and Insulin Sensitivity

Thyroid Function

PSA Monitoring for Men on GH Secretagogues

Fluid Retention

Monitoring Schedule Summary for GH Secretagogues

PT-141 / Bremelanotide (Vyleesi)

Blood Pressure Monitoring

Pigmentation Changes

BPC-157 and TB-500 / Thymosin Beta-4

GHK-Cu (Injectable / Systemic)

Thymosin Alpha-1

Combination Peptide Monitoring: When Multiple Compounds Are Used

Decision Criteria: Continue, Adjust, or Stop

Home Monitoring Tools Worth Having

When to Contact Your Provider Without Waiting

References

Read Next

Anti-Aging Peptide Protocols: A Framework for Evidence-Based Longevity Approaches

Anti-Aging Peptides: What the Research Actually Shows

AOD-9604 and Fragment 176-191: What the Clinical Trial Record Actually Shows

Ready to Apply These Insights?

Universal Baseline: Before Starting Any Peptide Therapy

How to Get Labs: Clinical vs. Direct-to-Consumer Options

Reading Results: What the Numbers Mean

IGF-1 Interpretation

HbA1c Interpretation

Kidney Function (eGFR) Interpretation

GLP-1 Receptor Agonists (Semaglutide, Tirzepatide, Liraglutide)

What to Monitor and When

GLP-1 Monitoring Schedule

Red-Flag Symptoms That Warrant Immediate Contact

Growth Hormone Secretagogues (Sermorelin, Ipamorelin, CJC-1295, Tesamorelin)

IGF-1: The Primary Monitoring Target

Glucose and Insulin Sensitivity

Thyroid Function

PSA Monitoring for Men on GH Secretagogues

Fluid Retention

Monitoring Schedule Summary for GH Secretagogues

PT-141 / Bremelanotide (Vyleesi)

Blood Pressure Monitoring

Pigmentation Changes

BPC-157 and TB-500 / Thymosin Beta-4

GHK-Cu (Injectable / Systemic)

Thymosin Alpha-1

Combination Peptide Monitoring: When Multiple Compounds Are Used

Decision Criteria: Continue, Adjust, or Stop

Home Monitoring Tools Worth Having

When to Contact Your Provider Without Waiting

References

Stay Informed on Peptide Research

Read Next

Anti-Aging Peptide Protocols: A Framework for Evidence-Based Longevity Approaches

Anti-Aging Peptides: What the Research Actually Shows

AOD-9604 and Fragment 176-191: What the Clinical Trial Record Actually Shows

Ready to Apply These Insights?